Pityriasis Rosea is Associated with Systemic Active Infection with Both Human Herpesvirus-7 and Human Herpesvirus-6

Takahiro Watanabe(Nagoya University), Jodi B. Black(National Cancer Institute), Elisabeth A. Aquilino(Washington Center), Andrew Blauvelt(Veterans Health Administration), Jan M. Orenstein(George Washington University), Tatsuyoshi Kawamura(University of Yamanashi), Sharon E. Jacob(University of California, Riverside)

Journal of Investigative Dermatology

October 1, 2002

10.1046/j.1523-1747.2002.00200.x

Cited by 187

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

|New England Journal of Medicine|2016|2k

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis

|Clinical Reviews in Allergy & Immunology|2018|738

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

|British Journal of Dermatology|2020|590

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

|The Lancet|2015|566

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

|The Lancet|2021|538